Individuals stroll in front of the Pfizer Inc. central offices, Aug. 8, 2025, located in New York.Angela Weiss/AFP via Getty Images
Earlier in the week, Pfizer, a medicine manufacturer, alongside its collaborator Valneva, revealed that a Lyme illness vaccine undergoing tests exhibited an efficiency rate surpassing 70% in advanced clinical examinations.
The prospect, PF-07307405, demonstrated a 73.2% effectiveness in diminishing validated instances of Lyme illness following the dispensation of the fourth and concluding dosage, in contrast with a placebo.
Nonetheless, the businesses communicated there were fewer instances of Lyme illness than projected during the trial phase, and the research fell short of a vital statistical criterion that assesses dependability, marginally missing the needed 20% mark at 15.8%.
Authorities on ailments transmitted by ticks communicated to ABC News their need to observe the complete information from the experiments, mentioning it is premature to ascertain the vaccine’s potential influence — while adding that the results are “promising.”
“Numerous other firms are attempting to formulate something, but those are distant by several years from nearing market availability,” stated Dr. Gene Shapiro, a professor specializing in pediatric infectious conditions and microbial illnesses epidemiology, to ABC News. “This vaccine was notably comparable to the vaccine recognized for its past success. I believe we should give attention to [this newer version].”
People walk outside the Pfizer Inc. headquarters, Aug. 8, 2025, in New York.Angela Weiss/AFP via Getty Images
Lyme illness constitutes a bacterial contagion propagated via the bite of blacklegged ticks, alternatively referred to as deer ticks, as per the Centers for Disease Control and Prevention (CDC).
Indications encompass fever, headache, exhaustion, and a skin eruption recognized as erythema migrans, states the CDC. If unaddressed, the contagion might disseminate to joints, the heart, and the nervous system.
Exceeding 89,000 Lyme illness occurrences were reported to the CDC by state health departments and the District of Columbia during 2023, in accordance with the newest data accessible from the federal health authority. Projections hint at approximately 476,000 Americans potentially undergoing diagnosis and care for Lyme illness on an annual basis.
Presently, no Lyme illness vaccine is procurable within the U.S. Formerly, a vaccine existed; however, it faced discontinuation in 2002, according to the CDC.
“The acceptance was inadequate. Sales figures were low, prompting the company’s decision to halt its sale,” Shapiro elucidated. “The vaccine presently under development [by Pfizer and Valneva] closely resembles that vaccine, incorporating only minor alterations.”
Dr. Martin Becker, a clinical associate professor within the medicine department at NYU Grossman Long Island School of Medicine, supplemented that apprehensions arose, notably concerning vaccine recipients encountering joint complications, though several studies probing for a link failed to establish a correlation.
Becker mentioned that numerous clinical experiments have been in progress, “but the one recently announced by Pfizer is, in my estimation, the most advanced,” he conveyed to ABC News. “We eagerly anticipated outcomes from this extensive Phase III experiment. Prior trials had already been issued, affirming the [vaccine’s] safety and immunogenicity.”
Pfizer and Valneva communicated their intentions to seek approval from the U.S. Food and Drug Administration, with Pfizer informing ABC News that the experiment’s conclusions indicate some degree of safeguarding against Lyme illness.
“It doesn’t imply it’s ineffective, though it signifies — had we observed greater infection incidence numbers — we would possess greater assurance concerning the extent of protection. It’s quite promising,” Becker remarked concerning not reaching the primary endpoint.
Lingering inquiries pertain to whether the vaccine, should it secure approval, will garner elevated acceptance compared to the preceding vaccine from decades ago.
A deer tick.STOCK PHOTO/Adobe
Shapiro expressed the potential for greater adoption of this vaccine contingent on the issuance of stronger endorsements. At the time of the prior vaccine’s clearance by federal regulators, Shapiro noted that the CDC’s Advisory Committee on Immunization Practices advocated considering the shot for individuals at heightened risk, while refraining from recommending it for those at minimal or nonexistent risk.
“It wasn’t a particularly robust recommendation,” Shapiro stated. “Moreover, there existed diminished awareness of Lyme illness. Consequently, it is highly probable that [the newer vaccine] would secure a more emphatic endorsement presently.”
Sourse: abcnews.go.com